1. Apabetalone (RVX-208) attenuates hyperglycemia and tmao induced adhesion of THP-1 monocytes to Huvec endothelial cells. (August 2018) Authors: Tsujikawa, L.; Kulikowski, E.; Calosing, C.; Wasiak, S.; Gilham, D.; Halliday, C.; Johansson, J.; Sweeney, M.; Wong, N. Journal: Atherosclerosis Issue: Volume 275(2018) Page Start: e167 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Apabetalone (Rvx-208) Attenuates Inflammatory Milieu Underlying Adhesion Of Monocytes To Endothelial Cells In Type 2 Diabetes Mellitus With Cardiovascular Disease Patients. (August 2019) Authors: Tsujikawa, L.; Kulikowski, E.; Rakai, B.; Fu, L.; Das, S.; Halliday, C.; Sarsons, C.; Daze, E.; Wasiak, S.; Gilham, D.; Johansson, J.; Sweeney, M.; Wong CW, N. Journal: Atherosclerosis Issue: Volume 287(2019) Page Start: e252 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Apabetalone (RVX-208) decreases atherogenic, thrombotic and inflammatory mediators in vitro and in plasma of patients with cardiovascular disease (CVD). (September 2016) Authors: Wong, N.; Kulikowski, E.; Wasiak, S.; Gilham, D.; Calosing, C.; Laura, T.; Halliday, C.; Johansson, J.; Sweeney, M. Journal: Atherosclerosis Issue: Volume 252(2016) Page Start: e245 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. RVX-208 a selective bromodomain extra-terminal protein inhibitor reduces mace in patients with high residual risks of cardiovascular disease, a post-hoc analysis. Issue 1 (July 2015) Authors: Wong, N.C.W.; Johansson, J.O.; Lebioda, K.; Halliday, C.; Kulikowski, E. Journal: Atherosclerosis Issue: Volume 241:Issue 1(2015) Page Start: e8 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗